The Canadian market has shown signs of stabilization, with the unemployment rate declining to 4.3% and inflation easing closer to the target range, despite ongoing uncertainties around trade agreements. In this context, penny stocks—typically representing smaller or newer companies—offer intriguing opportunities for investors looking for growth at lower price points. While often considered a niche investment area, these stocks can still provide value when backed by strong financial health and solid fundamentals.
Top 10 Penny Stocks In Canada
| Name |
Share Price |
Market Cap |
Financial Health Rating |
| Westbridge Renewable Energy (TSXV:WEB) |
CA$1.87 |
CA$47.27M |
★★★★★★ |
| Cannara Biotech (TSXV:LOVE) |
CA$1.80 |
CA$177.81M |
★★★★★★ |
| Zoomd Technologies (TSXV:ZOMD) |
CA$0.94 |
CA$94.75M |
★★★★★★ |
| Montero Mining and Exploration (TSXV:MON) |
CA$0.76 |
CA$6.35M |
★★★★★★ |
| CEMATRIX (TSX:CEMX) |
CA$0.36 |
CA$53.94M |
★★★★★★ |
| Monument Mining (TSXV:MMY) |
CA$1.16 |
CA$400.68M |
★★★★★★ |
| Thor Explorations (TSXV:THX) |
CA$1.54 |
CA$1.03B |
★★★★★★ |
| Pulse Seismic (TSX:PSD) |
CA$3.83 |
CA$194.24M |
★★★★★★ |
| Caldwell Partners International (TSX:CWL) |
CA$0.96 |
CA$28.34M |
★★★★★★ |
| Hemisphere Energy (TSXV:HME) |
CA$2.13 |
CA$200.93M |
★★★★★★ |
Click here to see the full list of 358 stocks from our TSX Penny Stocks screener.
Here's a peek at a few of the choices from the screener.
MediPharm Labs
Simply Wall St Financial Health Rating:★★★★★☆
Overview:MediPharm Labs Corp. is a pharmaceutical company specializing in the production and sale of purified cannabis extracts, concentrates, and advanced derivative products across Canada, Australia, Germany, and other international markets with a market cap of CA$29.74 million.
Operations:The company's revenue primarily comes from the production and sales of cannabis extracts and derivative products, totaling CA$46.10 million.
Market Cap:CA$29.74M
MediPharm Labs, with a market cap of CA$29.74 million, is navigating the competitive cannabis sector through strategic international expansion and key partnerships. Despite being unprofitable and not expected to turn profitable in the next three years, it has reduced its debt significantly and maintains more cash than total debt. Recent executive changes see Greg Hunter as Interim CEO, leveraging his extensive financial and operational expertise to enhance commercial strategies. The company recently signed a supply agreement with Remidose Aerosols Inc., expanding its reach into Costa Rica, while maintaining strong revenue growth in international markets.
Coast Copper
Simply Wall St Financial Health Rating:★★★★★★
Overview:Coast Copper Corp. is involved in the exploration and evaluation of mineral properties in Canada, with a market cap of CA$12.75 million.
Operations:There are no reported revenue segments for Coast Copper Corp.
Market Cap:CA$12.75M
Coast Copper Corp., with a market cap of CA$12.75 million, has recently transitioned to profitability, reporting net income of CA$1.09 million for Q3 2025. Despite being pre-revenue, the company benefits from strong financial positioning with short-term assets of CA$2.2 million far exceeding liabilities and no debt burden. Its price-to-earnings ratio of 18.1x is attractive compared to the industry average, while its return on equity stands high at 20.5%. However, investors should note its high volatility and reliance on non-cash earnings amidst a stable board tenure averaging 5.8 years.
Covalon Technologies
Simply Wall St Financial Health Rating:★★★★★★
Overview:Covalon Technologies Ltd. focuses on the research, development, manufacturing, and marketing of medical products related to infection management, advanced wound care, and surgical procedures across various global markets with a market cap of CA$44.42 million.
Operations:Covalon Technologies generates revenue from its Biotechnology (Startups) segment, which amounted to CA$32.82 million.
Market Cap:CA$44.42M
Covalon Technologies Ltd., with a market cap of CA$44.42 million, has demonstrated financial stability by maintaining short-term assets of CA$31.5 million that exceed both its long-term and short-term liabilities. The company is debt-free, having eliminated its previous debt-to-equity ratio of 194.6%. While Covalon's earnings have grown significantly over the past five years, recent performance shows a decline in net profit margins from 8.6% to 6.3%, and negative earnings growth at -22.9%. Despite these challenges, its price-to-earnings ratio remains competitive within the biotech industry average, reflecting potential value for investors.
Key Takeaways
-
Gain an insight into the universe of 358 TSX Penny Stocks by clicking here.
-
Interested In Other Possibilities? AI is about to change healthcare. These 106 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include TSX:LABS TSXV:COCO and TSXV:COV.
This article was originally published by Simply Wall St .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
